Results 31 to 40 of about 57,324 (252)
Adoptive T cell therapy for ovarian cancer. [PDF]
Gynecol OncolAlthough ovarian cancer patients typically respond to standard of care therapies, including chemotherapy and DNA repair inhibitors, the majority of tumors recur highlighting the need for alternative therapies. Ovarian cancer is an immunogenic cancer in which the accumulation of tumor infiltrating lymphocytes (TILs), particularly T cells, is associated ...
Gitto SB, Ihewulezi CJN, Powell DJ.
europepmc +3 more sources
Adoptive T Cell Therapy Following Haploidentical Hematopoietic Stem Cell Transplantation
Frontiers in Immunology, 2019 Delayed immune reconstitution and the consequently high rates of leukemia relapse and infectious complications are the main limitations of haploidentical hematopoietic stem cell transplantation.
Ping Zhang +3 more
doaj +1 more source
Adoptive B cell therapy for chronic viral infection
Frontiers in Immunology, 2022 T cell-based therapies have been widely explored for the treatment of cancer and chronic infection, but B cell-based therapies have remained largely unexplored.
Young Rock Chung +4 more
doaj +1 more source
European Journal of Case Reports in Internal MedicineIntroduction: Lung cancer is the second most common cancer worldwide and the leading cause of cancer deaths; non-small cell lung cancer (NSCLC) constitutes about 85% of lung cancer cases, with ALK fusions representing 3–6% of them.
Brenda Paola Rodriguez Arroyo +5 more
doaj +1 more source
Adoptive T-cell therapy for B-cell malignancies [PDF]
Expert Review of Hematology, 2009 The success of allogeneic hematopoietic cell transplantation (HCT) for B-cell malignancies is evidence that these tumors can be eliminated by T lymphocytes. This has encouraged the development of specific adoptive T-cell therapy, both for augmenting the anti-tumor effect of HCT and for patients not undergoing HCT.
Michael, Hudecek +3 more
openaire +2 more sources
Regulation of Memory CD8+ T Cell Differentiation by MicroRNAs
Cellular Physiology and Biochemistry, 2018 MicroRNAs (miRNAs) have emerged as crucial regulators of T lymphocyte survival, differentiation and function, all of which are key factors impacting the outcome of adoptive T cell-based immunotherapy.
Zhen Zhang +4 more
doaj +1 more source
Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy
Cells, 2020 T cell receptor (TCR)-based adoptive T cell therapies (ACT) hold great promise for the treatment of cancer, as TCRs can cover a broad range of target antigens.
Jan A. Rath, Caroline Arber
doaj +1 more source
To Remember or to Forget: The Role of Good and Bad Memories in Adoptive T Cell Therapy for Tumors
Frontiers in Immunology, 2020 The generation of immunological memory is a hallmark of adaptive immunity by which the immune system “remembers” a previous encounter with an antigen expressed by pathogens, tumors, or normal tissues; and, upon secondary encounters, mounts faster and ...
Anna Mondino, Teresa Manzo
doaj +1 more source
Chimeric Antigen Receptor T Cell Therapy in Hematology
Turkish Journal of Hematology, 2015 It is well demonstrated that the immune system can control and eliminate cancer cells. Immune-mediated elimination of tumor cells has been discovered and is the basis of both cancer vaccines and cellular therapies including hematopoietic stem cell ...
Pınar Ataca, Önder Arslan
doaj +1 more source
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Background Therapeutic apheresis (TA) is an established treatment modality for hematologic, neurologic, and immunologic disorders, yet access remains severely limited in sub‐Saharan Africa. Donor apheresis, including platelet apheresis collection from healthy donors, represents an important complementary modality supporting blood product ...
Nosa Bazuaye +33 more
wiley +1 more source